Compare Pfizer with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs NOVARTIS - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER NOVARTIS PFIZER/
NOVARTIS
 
P/E (TTM) x 44.9 2,112.6 2.1% View Chart
P/BV x 7.8 28.0 27.7% View Chart
Dividend Yield % 0.4 1.6 27.9%  

Financials

 PFIZER   NOVARTIS
EQUITY SHARE DATA
    PFIZER
Mar-19
NOVARTIS
Mar-19
PFIZER/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs3,840980 391.8%   
Low Rs2,080600 346.6%   
Sales per share (Unadj.) Rs455.0198.7 228.9%  
Earnings per share (Unadj.) Rs93.821.0 447.3%  
Cash flow per share (Unadj.) Rs109.422.3 491.5%  
Dividends per share (Unadj.) Rs22.5010.00 225.0%  
Dividend yield (eoy) %0.81.3 60.1%  
Book value per share (Unadj.) Rs658.2307.5 214.1%  
Shares outstanding (eoy) m45.7524.69 185.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.54.0 163.6%   
Avg P/E ratio x31.637.7 83.8%  
P/CF ratio (eoy) x27.135.5 76.2%  
Price / Book Value ratio x4.52.6 175.0%  
Dividend payout %24.047.7 50.3%   
Avg Mkt Cap Rs m135,42019,508 694.2%   
No. of employees `0002.60.6 452.8%   
Total wages/salary Rs m3,2381,171 276.5%   
Avg. sales/employee Rs Th7,911.48,445.4 93.7%   
Avg. wages/employee Rs Th1,230.92,015.7 61.1%   
Avg. net profit/employee Rs Th1,630.7891.0 183.0%   
INCOME DATA
Net Sales Rs m20,8154,907 424.2%  
Other income Rs m1,674783 213.9%   
Total revenues Rs m22,4895,689 395.3%   
Gross profit Rs m5,712123 4,651.5%  
Depreciation Rs m71432 2,245.0%   
Interest Rs m7316 458.5%   
Profit before tax Rs m6,599858 769.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,309340 679.0%   
Profit after tax Rs m4,291518 828.8%  
Gross profit margin %27.42.5 1,096.5%  
Effective tax rate %35.039.6 88.3%   
Net profit margin %20.610.6 195.4%  
BALANCE SHEET DATA
Current assets Rs m27,1678,055 337.3%   
Current liabilities Rs m8,9171,850 482.0%   
Net working cap to sales %87.7126.4 69.3%  
Current ratio x3.04.4 70.0%  
Inventory Days Days6845 150.6%  
Debtors Days Days3034 88.8%  
Net fixed assets Rs m8,862150 5,915.8%   
Share capital Rs m458123 370.7%   
"Free" reserves Rs m29,6567,469 397.1%   
Net worth Rs m30,1137,592 396.7%   
Long term debt Rs m250-   
Total assets Rs m39,4009,824 401.0%  
Interest coverage x91.554.9 166.6%   
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 105.8%   
Return on assets %11.15.4 203.9%  
Return on equity %14.26.8 208.9%  
Return on capital %22.111.5 192.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42858 743.6%   
Fx outflow Rs m7861,326 59.3%   
Net fx Rs m-358-1,269 28.2%   
CASH FLOW
From Operations Rs m978-1,943 -50.3%  
From Investments Rs m3512,742 12.8%  
From Financial Activity Rs m-1,099-298 368.4%  
Net Cashflow Rs m231501 46.0%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 63.9 75.0 85.2%  
Indian inst/Mut Fund % 7.5 2.0 375.0%  
FIIs % 4.9 1.6 306.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 21.5 110.2%  
Shareholders   85,207 41,647 204.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   SUVEN LIFESCIENCES  NEULAND LABS  PIRAMAL ENTERPRISES  PANACEA BIOTECH  ELDER PHARMA  

Compare PFIZER With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 127 Points Higher; Auto Stocks Witness Huge Buying(Closing)

Share markets in India continued to trade on a positive note during closing hours today and ended their session marginally higher.

Related Views on News

PFIZER Announces Quarterly Results (1QFY21); Net Profit Up 10.3% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, PFIZER has posted a net profit of Rs 1 bn (up 10.3% YoY). Sales on the other hand came in at Rs 5 bn (down 5.4% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My View on ITC(Fast Profits Daily)

Oct 23, 2020

What do the charts say about ITC?

The 'Seedhi Baat, No Bakwaas' View on ITC(Profit Hunter)

Oct 12, 2020

Is ITC an investment or a speculation at current levels?

Why ITC and not HUL is my Idea of a Good Investment Right Now(Views On News)

Oct 15, 2020

Rahul Shah discusses HUL's lost decade and its implications for ITC.

Why India's Drone Revolution is a 4x Profit Opportunity(Profit Hunter)

Oct 16, 2020

My research on India's leading defence companies brought me to one major player in drone manufacturing.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Oct 23, 2020 (Close)

TRACK PFIZER

PFIZER - ALEMBIC PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS